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Voltaire, after suffering an attack of small-
pox, wrote in a letter to Baron de Breteuil,
‘‘.the diseases that afflict us are as
different as the features on our faces’’
(1723). Systematic sequencing of cancer
genomes in the last 5 years has unmasked
the countless faces of cancer, laying bare
the uniqueness of each patient’s tumor; in
its cancer genes, its mutational pro-
cesses, its clonal architecture. And yet,
as Voltaire hints, we have known this—
we have known the unpredictability of
cancer outcomes in the clinic, the fact
that two patients can have apparently
identical cancers by every clinical mea-
sure and yet one die, one live. To under-
stand clinical variability, wemust embrace
the heterogeneity of cancer genomes. In
their complexity lie the myriad causa-
tive mutations, each defining cellular
behaviors that in toto dictate a cancer’s
path. Histology, metastasis, treatment
response, drug resistance—all are en-
coded in the cancer genome but in such
intricacy that robustly decoding them
requires sample sizes beyond those
completed thus far. We must match
cancer genomes to patients’ clinical out-
comes on a massive scale. We should
start with clinical trials, but explore the
systematic collation of genomic and clin-
ical data from routine hospital care as
sequencing enters the clinic. As theGlobal
Alliance intends, we should openly
discuss the ethical challenges, the clinical
descriptors, the database infrastructure,
the quality assurance that such an
endeavor entails. With a knowledge bank
of a million patients or more, cancer’s
many faces might become touchable.What’s Missing?
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The current cancer genome sequencing
projects have already revealed a number
of previously unknown recurring mutated
genes and unsuspected translocations.
Many of these have been confirmed by
targeted analyses of large patient sample
banks. These new genetic targets are
important because they expand the num-
ber of potential therapeutic targets as well
as increasing our understanding of the
range of cell biological processes that
contribute to malignant transformation.
Simultaneously, we have become in-
creasingly aware that perturbations of
other systems, such as DNA modifica-
tions due to conversion of methylC to
5hydroxy-methylC and modifications of
the histone tails of nucleosome compo-
nents, can have a profound effect on
the expression of ‘‘normal’’ genes as
assessed by standard DNA analysis. We
are just beginning to appreciate the
impact of noncoding RNAs, both short
and long on a host of genes. We need to
focus on the role of these and other
RNAs about which we are woefully igno-
rant, on the regulation of gene expression.
In fact, in addition to mining the huge
DNA sequencing database, constructing
an equally robust database of histone
modifications and RNA regulators of
gene expression is a major challenge for
the future. At present we have too limited
a view of what a biologically complete
analysis of the cancer ‘‘genotype’’ really
encompases!Cell 155,Thinking beyond Therapy
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The good news from genome-wide
sequencing studies of cancer over the
past 7 years is that there are only a limited
number of genes (150) and pathways
(12) that, when defective, are respon-
sible for all common forms of human
cancer (Vogelstein et al., Science 339,
1546–1558). The bad news from these
sequencing studies is that there are
multiple ways for cancers to develop
resistance to targeted therapeutics.
Such studies have highlighted how diffi-
cult it will be to produce prolonged remis-
sions, or cures, in patients with advanced
cancers. On the other hand, our new
appreciation of the cancer genome pro-
vides an opportunity to rethink our strate-
gies for reducing cancer deaths in the
long term. Deaths from most cancers are
preventable: sequencing as well as clin-
ical studies have shown that cancers
take decades to develop and are only
lethal at the end of this long process,
once metastasis has occurred. This time
frame provides a large window of oppor-
tunity for intervention prior to the onset
of metastatic disease. Innovative molecu-
lar and imaging-based approaches for
early detection based on the genetic
alterations and consequent pathway dis-
ruptions can open this window. When
combined with readily implementable
measures for cancer prevention (Colditz
et al., Sci. Transl. Med. 4, 127rv4), these
approaches have the capacity to reduce
deaths from cancer by 75% in the fore-
seeable future—even without any new
therapies.September 26, 2013 ª2013 Elsevier Inc. 9
Cancer Genomics in Context
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The Cancer Genome Atlas (TCGA) has
been a defining project of its era for
cancer medicine. Its impact rests on the
creation of a high quality and comprehen-
sive (up-to-date) genomic reference
that catalyzes identification of promising
therapeutic and diagnostic targets and
also drives fundamental discoveries in
cancer genetics and genome biology.
Yet, with its singular focus on in-depth
yet static characterization of primary un-
treated cancers, TCGA has not captured
the dynamic evolution of the cancer
genomes in context of metastatic pro-
gression and treatments. Although cata-
loguing the somatic genomic alterations
in cancer must continue, it is time for the
field to look beyond mining existing
data. The next big step will be to put
cancer genomics in appropriate clinical
context so we can establish complete
and longitudinal genomics to phenomics
(genotype-phenotype) correlations. Such
patient ‘‘big data’’ linked to longitudinal
clinical information collected during the
course of standard of care will accelerate
the acquisition of clinically actionable
insights. This will involve more than just
sequencing in setting of clinical trials.
Unlocking the full potential of cancer
genomics requires a radical change in
the culture of academic medicine to
create a new model of collaboration
between the basic research and clinical
enterprise to ensure the seamless integra-
tion of patient-oriented genomic research
in context of standard of clinical care
so that clinical information and research
data are efficiently and accurately
collected and linked. Finally, the regulato-
ry environment must support open role-
based data access to enable data-driven
discovery and iterative learning between
bench and bedside.10 Cell 155, September 26, 2013 ª2013 ElseCurious World beyond the Genome
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‘‘Curiouser and curiouser’’, Alice re-
marked as she entered a strange, inverted
world in Lewis Carrol’s classic, Through
the Looking Glass. For scientists and
physicians, the recent insights provided
by leukemia genomes can also be
described, rather aptly, as ‘‘curiouser
and curiouser’’. Take, for instance, the
identities of the most frequently mutated
genes in acute myelogenous leukemia
(AML). A majority are not traditional onco-
genes or tumor suppressors. Ras and p53
mutations are mutated, of course, but are
far less common than other genes whose
functions are mysterious. For example,
several labs, including ours, described
point mutations in the methyltransferase
DNMT3a in AML and in myelodysplastic
syndrome. But how does a gene that reg-
ulates DNA methylation across the
genome ultimately lead to the disordered
proliferation, clonal outgrowth, or dysre-
gulated self-renewal of myeloid cells ?
Indeed, as this list of genes mutated in
AML has grown, this problem of curious
identities has also grown more insistent.
There are mutations in genes that control
metabolism, RNA splicing, myeloid devel-
opment, and immune function. Where,
one might ask, are the good old onco-
genes? If there is an unfolding lesson
here, it is this: deciphering the cancer
genome marks a mere starting line in our
attempt to understand cancer. Function-
alizing the leukemia genome—under-
standing what the mutated genes do—is
the next major step in tackling cancer. It
is likely that this step will be even more
labor intensive than deciphering the
genome. But we cannot expect new
medicines for leukemia to emerge directly
from genomic insights. Unlike Alice, who
discovered shortcuts, we are stuck with
the long way home.vier Inc.A Million Genomes Ahead
Jun Wang
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Athough it is definitely a question whether
different types of cancer have similar
genomic alterations, we do not even
have sufficient samples to understand a
single type of cancer. Individuals with
different genetic and environmental
factors, such as carcinogen exposure,
commensal or pathogenic bacteria and
viruses, life style, and mental health, all
have to be sampled, both horizontally
and longitudinally. The interpretation of
cancer genomes relies on the scale and
quality of the sequencing data, innovative
handling of such big data and detailed
clinical and preclinical information. Early
and routine tests would be possible with
accurate and ultra-low input next-genera-
tion sequencing technologies, which
necessitate development of noninvasive
sampling approaches. Each sample
should be analyzed in a multiomic fashion
to be truly reliable and informative.
Single-cell sequencing is necessary for
elucidating the heterogeneity and recon-
structing the evolution of a cancer
sample. Biological investigations with
optimized humanized mouse models
and conditional reprogramming tumors
cells would be instrumental for develop-
ment and evaluation of drugs. Although
we envision a million ‘‘personalized’’
cancer genomes to come, the hope is to
integrate the large-scale, multidimen-
sional data in order to stratify each patient
or at-risk individual, for efficient diag-
nosis, prognosis and treatment.
